The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus

References

• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• FerranniniEGastaldelliAMiyazakiYMatsudaMMariADeFronzoRABetacell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysisJ Clin Endocrinol Metab20059049350015483086
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD)Diabetes Care2012351364137922517736
   PubMed Web of Science ®Google Scholar
• DandonaPChaudhuriAGhanimHMohantyPInsulin as an anti-inflammatory and antiatherogenic modulatorJ Am Coll Cardiol2009535 SupplS14S2019179212
   PubMed Web of Science ®Google Scholar
• YanHMaYLiYInsulin inhibits inflammation and promotes atherosclerotic plaque stability via PI3K-Akt pathway activationImmunol Lett201517071426681144
   PubMed Web of Science ®Google Scholar
• TakebayashiKAsoYInukaiTInitiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetesMetabolism20045369369915164314
   PubMed Web of Science ®Google Scholar
• BogdanskiPPupek-MusialikDDytfeldJInfluence of insulin therapy on expression of chemokinereceptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitusInt J Clin Pharmacol Ther20074556356717966842
   PubMed Web of Science ®Google Scholar
• MaoXMLiuHTaoXJYinGPLiQWangSKIndependent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetesDiabetes Metab Res Rev20092543544119405039
   PubMed Web of Science ®Google Scholar
• Aviles-SantaLSalinasKAdams-HuetBRaskinPInsulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitusJ Investig Med2006542031
   Web of Science ®Google Scholar
• PradhanADEverettBMCookNRRifaiNRidkerPMEffects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trialJAMA20093021186119419755697
   PubMed Web of Science ®Google Scholar
• GambleJMSimpsonSHEurichDTMajumdarSRJohnsonJAInsulin use and increased risk of mortality in type 2 diabetes: a cohort studyDiabetes Obes Metab201012475319788429
   PubMed Web of Science ®Google Scholar
• CurrieCJPooleCDEvansMPetersJRMorganCLMortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetesJ Clin Endocrinol Metab20139866867723372169
   PubMed Web of Science ®Google Scholar
• CurrieCJPetersJRTynanASurvival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort studyLancet201037548148920110121
   PubMed Web of Science ®Google Scholar
• ColaycoDCNiuFMcCombsJSCheethamTCA1C and cardiovascular outcomes in type 2 diabetes: a nested case-control studyDiabetes Care201134778320937686
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial InvestigatorsGersteinHCBoschJDagenaisGRBasal insulin and cardiovascular and other outcomes in dysglycemiaN Engl J Med201236731932822686416
   PubMed Web of Science ®Google Scholar
• FerranniniEDeFronzoRAImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetesEur Heart J2015362288229626063450
   PubMed Web of Science ®Google Scholar
• HoldenSEJenkins-JonesSMorganCLSchernthanerGCurrieCJGlucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancerDiabetes Obes Metab20151735036225399739
   PubMed Web of Science ®Google Scholar
• StoekenbroekRMRensingKLBernelot MoensSJHigh daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular eventsAtherosclerosis201524031832325864162
   PubMed Web of Science ®Google Scholar
• GambleJMChibrikovETwellsLKAssociation of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort studyLancet Diabetes Endocrinol20175435227865756
   PubMed Web of Science ®Google Scholar
• GersteinHCFerranniniERiddleMCORIGIN Trial InvestigatorsInsulin resistance and cardiovascular outcomes in the ORIGIN trialDiabetes Obes Metab20182056457028895655
   PubMed Web of Science ®Google Scholar
• NolanCJRudermanNBKahnSEPedersenOPrentkiMInsulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetesDiabetes20156467368625713189
   PubMed Web of Science ®Google Scholar
• BittencourtMSHajjarLAInsulin therapy in insulin resistance: could it be part of a lethal pathway?Atherosclerosis201524040040125890058
   PubMed Web of Science ®Google Scholar
• CaoWNingJYangXLiuZExcess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosisCurr Mol Pharmacol2011415416621241239
   PubMedGoogle Scholar
• Le Marchand-BrustelYMolecular mechanisms of insulin action in normal and insulin-resistant statesExp Clin Endocrinol Diabetes199910712613210320053
   PubMed Web of Science ®Google Scholar
• MonnierLHanefeldMSchnellOColetteCOwensDInsulin and atherosclerosis: how are they related?Diabetes Metab20133911111723507269
   PubMed Web of Science ®Google Scholar
• KhatanaSATaveiraTHDooleyAGWuWCThe association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitusJ Clin Hypertens (Greenwich)20101246246820591095
   PubMedGoogle Scholar
• MonnierLColetteCMichelFCristolJPOwensDRInsulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further studyDiabetes Metab Res Rev20112734835321309055
   PubMed Web of Science ®Google Scholar
• Szuszkiewicz-GarciaMMDavidsonJACardiovascular disease in diabetes mellitus: risk factors and medical therapyEndocrinol Metab Clin North Am201443254024582090
   PubMed Web of Science ®Google Scholar
• HameedIMasoodiSRMirSANabiMGhazanfarKGanaiBAType 2 diabetes mellitus: from a metabolic disorder to an inflammatory conditionWorld J Diabetes2015659861225987957
   PubMed Web of Science ®Google Scholar
• YangHJinXKei LamCWYanSKOxidative stress and diabetes mellitusClin Chem Lab Med2011491773178221810068
   PubMed Web of Science ®Google Scholar
• GluhovschiCGluhovschiGPetricaLUrinary biomarkers in the assessment of early diabetic nephropathyJ Diabetes Res20162016462612527413755
   PubMed Web of Science ®Google Scholar
• WangLLinPMaAC-peptide is independently associated with an increased risk of coronary artery disease in T2DM subjects: a cross-sectional studyPLoS One2015106e012711226098780
   PubMed Web of Science ®Google Scholar
• AntonopoulosASMargaritisMLeeRChannonKAntoniadesCStatins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trialsCurr Pharm Des2012181519153022364136
   PubMed Web of Science ®Google Scholar
• PacurariMKafouryRTchounwouPBNdebeleKThe renin-angiotensin-aldosterone system in vascular inflammation and remodelingInt J Inflam2014201468936024804145
   PubMedGoogle Scholar
• RidkerPMCushmanMStampferMPTracyRPHennekensCHInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy menN Engl J Med19973369739799077376
   PubMed Web of Science ®Google Scholar
• NitaCBalaCPorojanMHancuNFenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional studyDiabetol Metab Syndr201463024594096
   PubMed Web of Science ®Google Scholar
• NestiLNataliAMetformin effects on the heart and the cardiovascular system: a review of experimental and clinical dataNutr Metab Cardiovasc Dis20172765766928709719
   PubMed Web of Science ®Google Scholar
• ScheenAJEsserNPaquotNAntidiabetic agents: potential anti- inflammatory activity beyond glucose controlDiabetes Metab20154118319425794703
   PubMed Web of Science ®Google Scholar
• RidkerPMA Test in context: high-sensitivity C-reactive proteinJ Am Coll Cardiol20166771272326868696
   PubMed Web of Science ®Google Scholar
• MantovaniAGarlandaCBottazziBThe long pentraxin PTX3 in vascular pathologyVascul Pharmacol20064532633017023219
   PubMed Web of Science ®Google Scholar
• JennyNSBlumenthalRSKronmalRARotterJISiscovickDSPsatyBMAssociations of pentraxin 3 with cardiovascular disease: the multi-ethnic study of atherosclerosisJ Thromb Haemost201412999100524628740
   PubMed Web of Science ®Google Scholar
• BeckmanJSKoppenolWHNitric oxide, superoxide, and peroxynitrite: the good, the bad, and uglyAm J Physiol199627114241437
   PubMed Web of Science ®Google Scholar
• DaviesMJFuSWangHDeanRTStable markers of oxidant damage to proteins and their application in the study of human diseaseFree Radic Biol Med1999271151116310641706
   PubMed Web of Science ®Google Scholar
• NaruseRTakebayashiKMoritaKAsoYInukaiTComparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetesEndocr J2011581055106321986033
   PubMed Web of Science ®Google Scholar